[1]
Motomiya, Y. et al. 2024. Serum Levels of the C-terminal Fragment of Fibroblast Growth Factor 23 (C-FGF23) and Hepcidin in Patients with Hemodialysis Undergoing Treatment with a Proline Hydroxylase Domain (PHD) Inhibitor. Journal of Clinical Nephrology. 8, 3 (Oct. 2024), 132–137. DOI:https://doi.org/10.29328/journal.jcn.1001141.